Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy

被引：22
作者：
Danesi, R
Mosca, M
Boggi, U
Mosca, F
Del Tacca, M
机构：
[1] Univ Pisa, Dept Oncol,Transplants & Adv Technol, I-56126 Pisa, Italy
[2] Univ Pisa, Dept Internal Med, I-56126 Pisa, Italy
来源：
MOLECULAR MEDICINE TODAY | 2000年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1357-4310(00)01822-0
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The use of immunosuppressive agents in the treatment of transplant rejection and autoimmune disorders is gaining momentum, with significant improvements of both graft and patient survival. The individual response to drugs, however, is variable and unexpected toxicity, or impaired activity might be seen, as a result of molecular determinants that eventually dictate how the individual will respond to immunosuppressive agents. This review addresses a number of issues related to pharmacogenetics, and discusses how this approach might be used to improve the clinical efficacy and tolerability of therapeutic options for the management of organ transplantation and autoimmune disorders in the next decade.
引用
收藏
页码：475 / 482
页数：8
相关论文
共 39 条
  • [1] Immunosuppressive drugs, the first 50 years and a glance forward
    Allison, AC
    [J]. IMMUNOPHARMACOLOGY, 2000, 47 (2-3): : 63 - 83
  • [2] The 14-3-3 proteins positively regulate rapamycin-sensitive signaling
    Bertram, PG
    Zeng, CB
    Thorson, J
    Shaw, AS
    Zheng, XFS
    [J]. CURRENT BIOLOGY, 1998, 8 (23) : 1259 - 1267
  • [3] A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling
    Boytim, ML
    Lilly, P
    Drouvalakis, K
    Lyu, SC
    Jung, R
    Krensky, AM
    Clayberger, C
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 105 (10) : 1447 - 1453
  • [4] DOMINANT MISSENSE MUTATIONS IN A NOVEL YEAST PROTEIN RELATED TO MAMMALIAN PHOSPHATIDYLINOSITOL 3-KINASE AND VPS34 ABROGATE RAPAMYCIN CYTOTOXICITY
    CAFFERKEY, R
    YOUNG, PR
    MCLAUGHLIN, MM
    BERGSMA, DJ
    KOLTIN, Y
    SATHE, GM
    FAUCETTE, L
    ENG, WK
    JOHNSON, RK
    LIVI, GP
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (10) : 6012 - 6023
  • [5] MUTATIONS THAT PERTURB CYCLOPHILIN A LIGAND-BINDING POCKET CONFER CYCLOSPORINE-A RESISTANCE IN SACCHAROMYCES-CEREVISIAE
    CARDENAS, ME
    LIM, E
    HEITMAN, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (36) : 20997 - 21002
  • [6] Evaluation of the frequency of HLA determinants in patients with gingival overgrowth induced by cyclosporine-A
    Cebeci, I
    Kantarci, A
    Firatli, E
    Aygun, S
    Tanyeri, H
    Aydin, AE
    Carin, M
    Guc, U
    Tuncer, O
    [J]. JOURNAL OF CLINICAL PERIODONTOLOGY, 1996, 23 (08) : 737 - 742
  • [7] BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome
    Cesarman, E
    Chadburn, A
    Liu, YF
    Migliazza, A
    Dalla-Favera, R
    Knowles, DM
    [J]. BLOOD, 1998, 92 (07) : 2294 - 2302
  • [8] IDENTIFICATION OF AN 11-KDA FKBP12-RAPAMYCIN-BINDING DOMAIN WITHIN THE 289-KDA FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN AND CHARACTERIZATION OF A CRITICAL SERINE RESIDUE
    CHEN, J
    ZHENG, XF
    BROWN, EJ
    SCHREIBER, SL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) : 4947 - 4951
  • [9] Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy
    Colombel, JF
    Ferrari, N
    Debuysere, H
    Marteau, P
    Gendre, JP
    Bonaz, B
    Soulé, JC
    Modgliani, R
    Touze, Y
    Catala, P
    Libersa, C
    Broly, F
    [J]. GASTROENTEROLOGY, 2000, 118 (06) : 1025 - 1030
  • [10] DiPiro JT, 1999, PHARMACOTHERAPY PATH
1234